Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this trial is to assess the effect of switching CML patients, who have been treated with imatinib ≥ 2 years and who have stable detectable molecular residual disease between 0.01-1.0% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of patients who achieve confirmed MR4.0.
Critère d'inclusion
- Chronic myeloid leukemia